Stelis Biopharma

The company has entered into a binding term sheet with Stelis to acquire its Bengaluru-based Unit 3 biologics manufacturing unit, Syngene said in a late night statement on Tuesday.

Stelis Biopharma receives EIR from the US FDA for Drug-Device Combination Products

The US FDA’s EIR is received for the drug-device combination to be commercialised from the Stelis Pharma's flagship facility in Bengaluru, India

Strides Pharma arm gets EU-GMP certification for two facilities

Stelis Biopharma, an emerging biopharmaceutical and vaccine Contract Development and Manufacturing Organisation (CDMO) and the biologics arm of Strides Pharma, has received the European Union Goods Manufacturing Practices (EU-GMP) certification for the two manufacturing plants.

Stelis Biopharma receives EU compliance certificate for two facilities

Stelis recently entered into international partnerships to manufacture biologics for diabetes, osteoporosis, and other therapeutic categories using mammalian and microbial systems from pre-clinical development through the commercialisation of biologics, biosimilars, and vaccines

Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabs

Stelis Biopharma, the biopharmaceutical arm of Strides Pharma Science, said it could not sell 2.5 crore units of the single-dose vaccine manufactured by it due to several constraints following the Russian-Ukraine war.

Strides board approves $15 mn investment in Stelis Biopharma

The company's board has approved participation in the Series B fundraiser of Stelis Biopharma with a commitment of USD 15 million, Strides Pharma Science said in a regulatory filing.

Strides Shasun to demerge API, exit biotech & probiotic biz

"The structuring is directed towards having a sharper focus on compliance, supply chain and front-ends to provide the necessary growth impetus for its consumer facing formulations business," Strides said.

Regulatory claims on Agila settled, says Strides Shasun

There was some regulatory overhangs post Strides-Mylan Agila transaction, says Arun Kumar, Executive VC & MD of Strides Shasun.

GMS Holdings makes $8.49 mn investment in Strides arm

GMS Holding, through its subsidiary GMS Pharma (Singapore) Pte Ltd, has made a first tranche investment of USD 8.49 million in Stelis Biopharma Pvt Ltd, a subsidiary of the company, Strides Shasun said in a BSE filing.